Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2012 | 12:13am CEST
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
03/27 Johnson & Johnson Wins Its First Talc-Ovarian Cancer Case
03/26 General Motors, Walmart, Pepsico and FX Networks also suspend Google ads
03/26 US featured innovative medical technologies at Riyadh event
03/25 AT&T, Verizon halt Google ads over extremist videos
03/24 JOHNSON & JOHNSON : Innovation launches Singapore QuickFire Challenge Competitio..
03/24 AT&T and Johnson & Johnson Pull Ads From YouTube
03/24 OPPORTUNISM KNOCKS : Marketers and media take on Google
03/24 JOHNSON & JOHNSON : EPREX Marketing Authorisation Extended to Include Treatment ..
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/24 HOLOGIC : Global in-Vitro Diagnostics (IVD) Market-Danaher, Hologic, Alere, BD, ..
More news
Sector news : Pharmaceuticals - NEC
08:48aDJDuPont, Dow Get EU Approval for Merger -- WSJ
03/27DJALEXION PHARMACEUTICALS : Names New CEO Following Internal Sales-Practice Probe
03/27DJEU Clears Dow-DuPont Deal With Conditions -- 2nd Update
03/27DJEU Clears Dow-DuPont Deal With Conditions -- Update
03/27 Chinese drug approval boosts AstraZeneca's lung cancer hopes
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/27 My Favorite Biotech Takeover Play
03/27 Quiet Rumblings From The Credit Markets
03/27 COFFEE WITH MOHNISH PABRAI : Investor Tips & Categories Of Business
03/27 Karyopharm's Selinexor Should Drive Substantial Growth
03/27 UPDATE : Portfolio123 Designer Low Volatility Portfolio
Advertisement
Financials ($)
Sales 2017 74 632 M
EBIT 2017 23 011 M
Net income 2017 17 928 M
Finance 2017 21 362 M
Yield 2017 2,66%
P/E ratio 2017 19,06
P/E ratio 2018 17,78
EV / Sales 2017 4,28x
EV / Sales 2018 4,02x
Capitalization 341 030 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 127 $
Spread / Average Target 1,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.91%341 030
ROCHE HOLDING LTD.8.73%220 248
PFIZER INC.5.23%203 546
NOVARTIS AG-0.47%195 735
MERCK & CO., INC.7.34%173 493
SANOFI7.76%117 163
More Results